Skip to contentR
REGENXBIO Inc.
R
RGNXREGENXBIO Inc. Q3 2025 · 10-Q
Revenue$29.73M$29.73M+22.9% vs Q3 2024 Net Income-$61.94M-$61.94MN/M vs Q3 2024 EPS Diluted-$1.20-$1.20N/M vs Q3 2024 Operating Income-$52,411,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
REGENXBIO Inc. · CIK 1590877 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$56,451,000N/M Margins · derivedOperating margin-176.3%+80.3 pt vs Q3 2024
Net margin-208.3%+38.0 pt vs Q3 2024
ended Sep 30, 2025 · filed Nov 6, 2025 · 37 d after period end